MedTrace Logo

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

NCT02689284 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-03-17

Study results available
· View outcomes & findings →

Summary

This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.

Conditions

Interventions

BIOLOGICAL

Margetuximab 10 mg/kg

Margetuximab treatment is administered intravenously (IV) once every 21-day cycle

BIOLOGICAL

Margetuximab 15 mg

Margetuximab treatment is administered IV once every 21-day cycle

BIOLOGICAL

Pembrolizumab

Pembrolizumab treatment is administered IV once every 21-day cycle

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • United States
  • Canada
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02689284 on ClinicalTrials.gov